| Title |
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach
|
|---|---|
| Published in |
Drug Design, Development and Therapy, July 2012
|
| DOI | 10.2147/dddt.s8927 |
| Pubmed ID | |
| Authors |
Claudio Gasperini, Serena Ruggieri |
| Abstract |
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, traditionally considered to be an autoimmune, demyelinating disease. Based on this understanding, the initial therapeutic strategies were directed at immune modulation and inflammation control. At present, there are five licensed first-line disease-modifying drugs and two second-line treatments in MS. Currently available MS therapies have shown significant efficacy throughout many trials, but they produce different side-effect profiles in patients. Since they are well known and safe, they require regular and frequent parenteral administration and are associated with limited long-term treatment adherence. Thus, there is an important need for the development of new therapeutic strategies. Several oral compounds are in late-stage development for treating MS. Fingolimod (FTY720; Novartis, Basel, Switzerland) is an oral sphingosine-1-phosphase receptor modulator which has demonstrated superior efficacy compared with placebo and interferon β-1a in Phase III studies and has been approved in the treatment of MS. We summarily review the oral compounds in study, focusing on the recent development, approval and the clinical experience with FTY720. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Portugal | 1 | 1% |
| Uruguay | 1 | 1% |
| Italy | 1 | 1% |
| Unknown | 90 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 15% |
| Researcher | 12 | 13% |
| Student > Master | 10 | 11% |
| Student > Bachelor | 10 | 11% |
| Other | 9 | 10% |
| Other | 24 | 26% |
| Unknown | 15 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 39% |
| Agricultural and Biological Sciences | 9 | 10% |
| Psychology | 5 | 5% |
| Chemistry | 4 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Other | 17 | 18% |
| Unknown | 18 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 September 2018.
All research outputs
#3,452,687
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#203
of 2,254 outputs
Outputs of similar age
#21,934
of 177,038 outputs
Outputs of similar age from Drug Design, Development and Therapy
#2
of 4 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,038 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.